We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ADVOCATE | ANCA Associated Vasculitis
Previous Study | Return to List | Next Study

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (ADVOCATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02994927
Recruitment Status : Completed
First Posted : December 16, 2016
Results First Posted : September 9, 2022
Last Update Posted : October 13, 2022
Sponsor:
Information provided by (Responsible Party):
ChemoCentryx

Brief Summary:
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.

Condition or disease Intervention/treatment Phase
ANCA-Associated Vasculitis Drug: Avacopan Drug: Prednisone Drug: Cyclophosphamide Biological: Rituximab Drug: Azathioprine Phase 3

Detailed Description:

Complement 5a and its receptor C5aR (CD88) are involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

This is a randomized, double-blind, active-controlled Phase 3 study to evaluate the safety and efficacy of the orally-administered, selective C5aR inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated concomitantly with Rituximab or Cyclophosphamide/Azathioprine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 331 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: This study was double-blind, double-dummy, i.e., placebo capsules were identical in appearance to the avacopan capsules, and prednisone capsules also had matching placebo capsules. To maintain the blind, multiple measures were taken (i.e., randomization code was not accessible to study personnel who had contact with study centers or who were involved in data management and analysis for the duration of the study).
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine
Actual Study Start Date : March 15, 2017
Actual Primary Completion Date : September 7, 2019
Actual Study Completion Date : November 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Steroids Vasculitis

Arm Intervention/treatment
Active Comparator: Prednisone group
Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Drug: Prednisone

Avacopan-matching placebo twice daily orally for 52 weeks (364 days):

- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.

Oral prednisone tapering regimen over 20 weeks (140 days):

  • Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was <55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.
  • Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day.

Drug: Cyclophosphamide
Orally or intravenously administered

Biological: Rituximab
Intravenously administered

Drug: Azathioprine
Orally administered

Experimental: Avacopan group
Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Drug: Avacopan

Avacopan 30 mg twice daily orally for 52 weeks (364 days):

- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.

Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):

  • Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was <55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.
  • Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day.
Other Name: CCX168

Drug: Cyclophosphamide
Orally or intravenously administered

Biological: Rituximab
Intravenously administered

Drug: Azathioprine
Orally administered




Primary Outcome Measures :
  1. Percentage of Subjects Achieving Disease Remission at Week 26 [ Time Frame: Week 26 ]

    Disease remission at Week 26 was defined as:

    • Achieving a BVAS of 0 as determined by the Adjudication Committee;
    • No administration of glucocorticoids given for ANCA-associated vasculitis within 4 weeks prior to Week 26;
    • No BVAS >0 during the 4 weeks prior to Week 26 (if collected for an unscheduled assessment).

  2. Percentage of Subjects Achieving Sustained Disease Remission at Week 52 [ Time Frame: Week 52 ]

    Sustained remission at Week 52 was defined as:

    • Disease remission at Week 26 as defined above;
    • Disease remission at Week 52 defined as a BVAS of 0 at Week 52 as determined by the Adjudication Committee and no administration of glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to Week 52;
    • No disease relapse between Week 26 and Week 52 as determined by the Adjudication Committee.


Secondary Outcome Measures :
  1. Subject Incidence of Treatment-emergent SAEs, AEs, and Withdrawals Due to AEs [ Time Frame: From day 1 throughout the study period (day 421/week 60) ]

    AEs=Adverse events

    SAEs=Serious adverse events

    TEAE=Treatment-emergent adverse event


  2. Glucocorticoid-induced Toxicity as Measured by Change From Baseline Over the First 26 Weeks in the GTI [ Time Frame: Baseline, Week 13 and 26 ]

    GTI-CWS=Glucocorticoid Toxicity Index Cumulative Worsening Score;

    GTI-AIS=Glucocorticoid Toxicity Index Aggregate Improvement Score;

    The Glucocorticoid Toxicity Index (GTI) was developed to score glucocorticoid toxicity. The GTI includes: the Cumulative Worsening Score (CWS) that captures cumulative toxicity, both permanent and transient, over the course of time (serves as a cumulative record of toxicity); and the Aggregate Improvement Score that captures both improvement and worsening of toxicity over time (serves as a record of both improving and worsening toxicity). Both scores range from 0 (best health) to 100 (worst health).


  3. Percentage of Participants With BVAS of 0 at Week 4, Regardless of Whether the Subjects Received Glucocorticoids During This Period of Time and Based on Assessment by the Blinded AC [ Time Frame: Week 4 ]

    AC=Adjudication Committee; BVAS=Birmingham Vasculitis Activity Score;

    The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).


  4. Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index [ Time Frame: Baseline, Week 26 and 52 ]

    SF-36v2: Measure of health- related quality of life (Medical Outcomes Survey Short Form-36 version 2)

    EQ-5D-5L: EuroQuality of Life-5 Domains-5 Levels

    The SF-36v2 component scores and the EQ-5D-5L VAS score range from 0 (worst health) to 100 (best health). The EQ-5D-5L Index Score ranges from 0 (worst health) to 1 (best health).


  5. Percentage of Subjects and Time to Experiencing a Relapse After Previously Achieving Remission at Week 26 in the Study [ Time Frame: Week 52 ]

    The median time to relapse was not estimable because of small number of relapsed subjects.

    A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after:

    1. having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or
    2. having achieved BVAS=0 at any time during the treatment period

    ANCA=anti-neutrophil cytoplasmic autoantibody; BVAS=Birmingham Vasculitis Activity Score; The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).


  6. Percentage of Subjects and Time to Experiencing a Relapse After Previously Achieving BVAS=0 at Any Time During the Treatment Period [ Time Frame: Week 52 ]

    The median time to relapse was not estimable because of small number of relapsed subjects.

    A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after:

    1. having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or
    2. having achieved BVAS=0 at any time during the treatment period

    The Birmingham Vasculitis Activity Score (BVAS) form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).


  7. In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), the Change in eGFR From Baseline Over 52 Weeks [ Time Frame: Baseline, Week 26 and 52 ]

    Change from baseline in kidney function, as measured by eGFR (based on the MDRD equation), was measured in subjects with renal disease based on the BVAS renal component.

    eGFR=estimated glomerular filtration rate

    BVAS=Birmingham Vasculitis Activity Score

    MDRD=Modification of Diet in Renal Disease


  8. In Subjects With Renal Disease and Albuminuria at Baseline (Based in the BVAS Renal Component), the Percent Change in UACR From Baseline Over 52 Weeks [ Time Frame: Baseline, Week 4, 26 and 52 ]

    BVAS=Birmingham Vasculitis Activity Score

    UACR=Urinary albumin:creatinine ratio


  9. In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), the Percent Change in Urinary MCP-1:Creatinine Ratio From Baseline Over 52 Weeks [ Time Frame: Baseline, Week 26 and 52 ]

    BVAS=Birmingham Vasculitis Activity Score

    MCP-1=monocyte chemoattractant protein-1


  10. Change in the VDI From Baseline Over 52 Weeks, Including the Week 26 and Week 52 Time Points [ Time Frame: Baseline, Week 26 and 52 ]
    VDI=Vasculitis Damage Index; The VDI is comprised of 64 items of damage, grouped into 11 organ-based systems or categorizations. Damage is defined as the presence of non-healing scars and does not give any indication of current disease activity. Damage is also defined as having been present or currently present for at least 3 months. Completion of the form provides a numerical score, which ranges from 0 (best health) to 64 (worst health).

  11. Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (1/5) [ Time Frame: Baseline, Week 26 and 52 ]
  12. Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5) [ Time Frame: Baseline, Week 26 and 52 ]
  13. Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (3/5) [ Time Frame: Baseline, Week 26 and 52 ]
  14. Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (4/5) [ Time Frame: Baseline, Week 26 and 52 ]
  15. Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (5/5) [ Time Frame: Baseline, Week 26 and 52 ]
  16. Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2) [ Time Frame: Baseline, Week 26 and 52 ]
  17. Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2) [ Time Frame: Baseline, Week 26 and 52 ]
  18. Change From Baseline in Vital Signs (1/5) [ Time Frame: Baseline, Week 26 and 52 ]
  19. Change From Baseline in Vital Signs (2/5) [ Time Frame: Baseline, Week 26 and 52 ]
  20. Change From Baseline in Vital Signs (3/5) [ Time Frame: Baseline, Week 26 and 52 ]
  21. Change From Baseline in Vital Signs (4/5) [ Time Frame: Baseline, Week 26 and 52 ]
  22. Change From Baseline in Vital Signs (5/5) [ Time Frame: Baseline, Week 26 and 52 ]
    BMI=Body Mass Index

  23. Number of Subjects With Clinically Significant ECG Changes From Baseline [ Time Frame: From day 1 throughout the study period (day 421/week 60) ]

    Clinical significance was assessed by the individual reading of the ECGs

    ECG=Electrocardiogram


  24. Number of Subjects Where a Relationship Between Avacopan/Placebo, Glucocorticoid Use, Cyclophosphamide, Rituximab, and Azathioprine or Mycophenolate Use to an AE Was Determined by the Investigator [ Time Frame: From day 1 throughout the study period (day 421/week 60) ]
    AE=Adverse Event

  25. Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity [ Time Frame: From day 1 throughout the study period (day 421/week 60) ]

    WBC=White Blood Cell

    TEAE=Treatment-Emergent Adverse Event


  26. Number of Subjects Experiencing a Relapse After Previously Achieving BVAS=0 During the Study [ Time Frame: From day 1 throughout the study period (day 421/week 60) ]

    BVAS=Birmingham Vasculitis Activity Score;

    A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after:

    1. having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or
    2. having achieved BVAS=0 at any time during the treatment period

    The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis
  • Male and female subjects, aged at least 18 years, with newly-diagnosed or relapsed associated vasculitis (AAV) where treatment with cyclophosphamide or rituximab is needed; where approved by Regulatory Agencies, adolescents (12-17 year old) may be enrolled
  • Use of adequate contraception
  • Positive test for anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO)
  • At least 1 major item, or at least 3 non-major items, or at least the 2 renal items of proteinuria and hematuria on Birmingham Vasculitis Activity Score (BVAS)
  • Estimated glomerular filtration rate ≥15 mL/minute/1.73 m^2 at screening

Exclusion Criteria:

  • Pregnant or breast-feeding
  • Alveolar hemorrhage requiring pulmonary ventilation support at screening
  • Any other known multi-system autoimmune disease
  • Required dialysis or plasma exchange within 12 weeks prior to screening
  • Have a kidney transplant
  • Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1
  • Received intravenous glucocorticoids, >3000 mg methylprednisolone equivalent, within 4 weeks prior to screening
  • Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to screening
  • Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred (i.e., CD19 count > 0.01x10^9/L); received anti-tumor necrosis factor (TNF) treatment, abatacept, alemtuzumab, intravenous immunoglobulin (IVIg), belimumab, tocilizumab, or eculizumab within 12 weeks prior to screening
  • For patients scheduled to receive cyclophosphamide treatment, urinary outflow obstruction, active infection (especially varicella zoster infection), or platelet count <50,000/μL before start of dosing
  • Participated previously in a CCX168 study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02994927


Locations
Show Show 198 study locations
Sponsors and Collaborators
ChemoCentryx
Investigators
Layout table for investigator information
Study Director: Clinical trials Disclosure ChemoCentryx, Inc.
  Study Documents (Full-Text)

Documents provided by ChemoCentryx:
Study Protocol  [PDF] January 18, 2019
Statistical Analysis Plan  [PDF] October 28, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: ChemoCentryx
ClinicalTrials.gov Identifier: NCT02994927    
Other Study ID Numbers: CL010_168
ADVOCATE ( Other Identifier: ChemoCentryx )
First Posted: December 16, 2016    Key Record Dates
Results First Posted: September 9, 2022
Last Update Posted: October 13, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ChemoCentryx:
ANCA-associated vasculitis
complement
vasculitis
C5aR
avacopan
CCX168
MPA
GPA
Additional relevant MeSH terms:
Layout table for MeSH terms
Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Systemic Vasculitis
Vascular Diseases
Cardiovascular Diseases
Autoimmune Diseases
Immune System Diseases
Prednisone
Cyclophosphamide
Rituximab
Azathioprine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antimetabolites
Antimetabolites, Antineoplastic